| Code | CSB-RA004929MB10HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to SG301, targeting CD38, a type II transmembrane glycoprotein that functions as both an ectoenzyme and receptor. CD38 catalyzes the synthesis and hydrolysis of cyclic ADP-ribose and ADP-ribose from NAD+, playing crucial roles in calcium signaling, cell adhesion, and signal transduction. This protein is widely expressed on immune cells, including plasma cells, activated T cells, B cells, and natural killer cells. CD38 has emerged as a significant therapeutic target due to its high expression on multiple myeloma cells and various hematological malignancies, as well as its involvement in immune regulation and inflammatory processes.
SG301 serves as a reference antibody in the development of CD38-targeted therapeutics and diagnostic tools. This biosimilar antibody provides researchers with a valuable tool for investigating CD38 biology, exploring its role in cancer immunology, studying plasma cell disorders, and evaluating immune cell dynamics. It supports studies examining CD38-mediated signaling pathways, NAD+ metabolism, and the mechanisms underlying CD38-targeted therapies in oncology and autoimmune research.
There are currently no reviews for this product.